Jake Orlick, an 11-year-old boy, is fighting a courageous battle against Ewing Sarcoma, a rare form of bone cancer. Our Patrick Grohar, MD, PhD, an attending physician with the Cancer Center and the Director of Translational Research with the Center of Childhood Cancer Research, may be on the verge of a breakthrough with a novel new experimental treatment for relapsed Ewing sarcoma.

Patrick Grohar, MD, PhD, an attending physician with the Cancer Center and the Director of Translational Research with the Center of Childhood Cancer Research, is set to launch a novel, experimental approach to treating relapsed Ewing sarcoma, as highlighted in this story in the Philadelphia Inquirer.

Caregiver burnout is not only normal, but inevitable. A CHOP psychologist offers advice for struggling families.

This case study highlights a multimodal approach to surgical management of osteosarcomas in young children, maximizing control while providing a functional limb that will grow with the child.

Patrick J. Grohar, MD, PhD, focuses on developing therapies for a cancer that’s rare in adults but relatively common in the pediatric population.

CHOP has opened a phase 1 trial using CAR T for tough acute myeloid leukemia, hoping to replicate the therapy’s success for acute lymphoblastic leukemia.

A CHOP program is focused on identifying children who are predisposed to develop cancer and using surveillance testing to detect cancers early.

An unrelenting, deep bone pain that woke him up from sleep is what led to Jake’s diagnosis just last March of Ewing sarcoma, one of the most common bone tumors in children and adolescents.

The National Academy of Medicine elects two global leaders in cellular and gene therapy from Children’s Hospital of Philadelphia.

Stephan Grupp, MD, PhD, Chief of the Cell Therapy and Transplant Section in the Division of Oncology, has been elected into the National Academy of Medicine (NAM).